TPMT Enzyme Activity (Thiopurine Methyl Transferase) Genotype Study - Plasma

TPMT Enzyme Activity (Thiopurine Methyl Transferase) Genotype Study is a specialised pharmacogenetic and pharmacology-related laboratory investigation used to evaluate how a patient may metabolise thiopurine medicines. Thiopurines include azathioprine, mercaptopurine and thioguanine. These medicines are used in selected patients with inflammatory bowel disease, autoimmune disorders, rheumatological conditions, dermatological diseases, organ transplantation and certain blood cancers.

Thiopurine methyltransferase, abbreviated as TPMT, is an enzyme involved in the metabolism and inactivation of thiopurine medicines. TPMT activity varies between individuals. Some people have normal enzyme activity, some have intermediate activity and a small proportion have very low or absent activity. Patients with reduced TPMT function may accumulate excessive concentrations of active thiopurine metabolites and have an increased risk of profound bone marrow suppression, low blood cell counts, infection, bleeding and other serious treatment-related complications when conventional doses are used.

TPMT status can be evaluated by two different approaches. A phenotype or enzyme activity test measures the functional activity of TPMT in red blood cells. A genotype test examines the TPMT gene for selected variants associated with reduced or absent enzyme function. These approaches provide related but not identical information. The referring clinician and laboratory should confirm whether enzyme activity, genotyping or a combined assessment has been ordered.

The catalogue name includes enzyme activity, genotype study and plasma terminology. However, laboratories commonly perform TPMT enzyme activity using erythrocytes from an EDTA whole-blood specimen, while genotyping generally uses DNA extracted from whole blood or another validated cellular specimen. Plasma alone usually does not contain the red blood cells needed for a conventional TPMT activity assay. Patients and collection staff should therefore verify the exact method, specimen type, collection tube and transport requirements with Focus Diagnostics before sample collection.

TPMT testing helps clinicians select a safer initial treatment strategy, but it does not replace regular complete blood counts, liver function tests, clinical observation or therapeutic drug monitoring. Normal TPMT findings do not eliminate the possibility of toxicity because other genetic, clinical and treatment-related factors can influence thiopurine response.

Benefits of TPMT Testing

The principal benefit of TPMT assessment is identifying patients who may have an increased risk of severe thiopurine-related myelosuppression before or during treatment. Results allow the treating specialist to consider an appropriate starting dose, closer monitoring or an alternative medicine based on the patient's overall clinical circumstances.

• Assesses an important pathway involved in azathioprine, mercaptopurine and thioguanine metabolism.
• Helps identify patients with reduced or absent TPMT function.
• Supports safer selection of the initial thiopurine treatment strategy.
• May reduce the risk of severe bone marrow toxicity when results are used with clinical guidelines.
• Helps distinguish normal, intermediate and poor TPMT metaboliser categories.
• May support evaluation of unexpected toxicity during thiopurine therapy.
• Provides pharmacogenetic information that usually remains relevant throughout life when genotyping is performed.
• Complements complete blood counts, liver function tests and thiopurine metabolite monitoring.
• Supports personalised treatment decisions by gastroenterologists, oncologists, haematologists, rheumatologists and transplant specialists.
• May help determine whether additional NUDT15 testing should be considered.

Clinical Indications and Applications

Before Starting Thiopurine Treatment: TPMT testing is commonly considered before initiating azathioprine, mercaptopurine or thioguanine. Identifying reduced TPMT activity or clinically relevant genetic variants can help the prescribing physician select an adjusted starting regimen or consider a non-thiopurine alternative.

Inflammatory Bowel Disease: Azathioprine and mercaptopurine may be prescribed in selected patients with Crohn's disease or ulcerative colitis. TPMT assessment can contribute to treatment planning, but it does not predict whether the medicine will adequately control the disease or whether every type of adverse effect will occur.

Haematology and Oncology: Mercaptopurine and thioguanine form part of treatment protocols for certain leukaemias and other haematological conditions. TPMT results must be interpreted within the specific oncology protocol because dose intensity, accompanying medicines and therapeutic objectives differ from those used for autoimmune diseases.

Autoimmune and Rheumatological Conditions: Azathioprine may be used for selected autoimmune, rheumatological and dermatological disorders. TPMT testing can help assess metabolic risk before treatment, while ongoing safety monitoring remains necessary throughout therapy.

Unexpected Bone Marrow Suppression: Testing may be considered when a patient develops an unexpectedly severe reduction in white blood cells, neutrophils, platelets or haemoglobin during thiopurine therapy. Treatment-related cytopenia can have causes other than TPMT deficiency, so urgent clinical assessment and broader investigation may be required.

TPMT Enzyme Activity and TPMT Genotype

TPMT Enzyme Activity Testing: Phenotype testing directly measures how actively TPMT functions in the patient's erythrocytes. The result may be reported as low, intermediate, normal or high activity, often with a numerical value and a method-specific reference range. Because it measures current enzyme function, it can be affected by blood transfusion, red blood cell disorders, medications and laboratory methodology.

TPMT Genotype Testing: Genotyping examines DNA for selected variants in the TPMT gene. The laboratory uses the identified alleles to predict a metaboliser phenotype, such as normal, intermediate or poor metaboliser. Genotyping is generally not altered by most medicines. However, a targeted panel may not detect every rare or previously uncharacterised TPMT variant, so a result showing no tested variant does not guarantee normal enzyme activity.

Combined Interpretation: Genotype and enzyme activity results usually agree but can occasionally be discordant. Recent blood transfusion, allogeneic stem cell transplantation, rare genetic variants, medication effects or technical factors can cause discrepancies. When results do not agree, the treating specialist may discuss the case with the testing laboratory or a pharmacogenetics professional before making treatment decisions.

Role of NUDT15 Testing

TPMT is not the only genetic factor associated with thiopurine intolerance. Variants in the NUDT15 gene can also substantially increase the risk of thiopurine-related bone marrow toxicity. NUDT15 variants are particularly important in several Asian populations but may occur in people of any ancestry.

A TPMT enzyme activity test cannot detect NUDT15 variants. A TPMT-only genotype study also does not evaluate NUDT15 unless that gene is specifically included in the ordered panel. The treating physician may therefore recommend combined TPMT and NUDT15 genotyping, especially before thiopurine treatment or when severe myelosuppression occurs despite apparently normal TPMT findings.

Why Doctors Recommend This Test

Thiopurine medicines have a narrow therapeutic range. Inadequate exposure may reduce effectiveness, while excessive active metabolite concentrations can damage the bone marrow and cause dangerous reductions in blood cell counts. TPMT testing provides information that can help clinicians estimate part of this metabolic risk before significant exposure occurs.

A poor TPMT metaboliser may be at particularly high risk of severe or life-threatening toxicity when treated with conventional thiopurine doses. An intermediate metaboliser may also require an adjusted starting strategy and closer monitoring. A normal metaboliser can generally receive the conventional starting approach appropriate for the condition, but routine monitoring remains essential because normal TPMT function does not prevent every adverse reaction.

TPMT testing does not prescribe a dose automatically. Dose selection depends on the exact medicine, diagnosis, treatment protocol, age, body size, liver and kidney function, accompanying drugs, infection risk and results from TPMT and possibly NUDT15 assessment. Only the treating specialist should initiate, adjust or discontinue thiopurine medication.

Preparation Before the Test

Fasting is generally not required unless the laboratory or referring doctor gives different instructions. Patients should inform the collection team about all current medicines, previous thiopurine exposure, recent blood transfusions, bone marrow or stem cell transplantation and diagnosed blood disorders.

Certain medicines may inhibit TPMT activity in vitro or influence phenotypic interpretation. Patients must not stop ibuprofen, naproxen, sulfasalazine, mesalamine, methotrexate, diuretics or any other prescribed medicine without medical instructions. The laboratory or physician will determine whether timing changes are necessary for the specific activity assay.

A recent red blood cell transfusion can make TPMT enzyme activity reflect donor cells rather than the patient's own activity. This can produce a misleading phenotype result. Genotyping may be preferred in some transfused patients, but allogeneic stem cell transplantation creates additional interpretation issues because blood-cell DNA may represent the donor. The laboratory must be informed about these procedures before testing.

Sample Collection Procedure

A trained phlebotomist collects a venous blood sample using the tube specified by the performing laboratory. TPMT enzyme activity is usually assessed in erythrocytes from anticoagulated whole blood. Genotype testing generally requires a whole-blood specimen containing white blood cells from which DNA can be extracted.

The sample must be correctly labelled and transported under validated conditions. The required tube, volume, storage temperature and stability period depend on whether activity testing, genotype testing or both are performed. A clotted, haemolysed, insufficient, incorrectly stored or incorrectly labelled specimen may be rejected.

Because the catalogue title refers to plasma despite including enzyme activity and genotyping, patients should not assume that a routine plasma sample is sufficient. The collection centre must verify the exact referral-laboratory requirements before drawing and processing the sample.

Laboratory Analysis and Reporting

TPMT enzyme activity may be measured using a validated biochemical method such as liquid chromatography with mass spectrometric detection. The assay measures the formation of methylated metabolites in red blood cells. Results are interpreted using the performing laboratory's reference interval and may be classified into activity categories.

TPMT genotyping uses a validated molecular method to detect specified variants or alleles. The report may list the detected diplotype and assign a predicted phenotype. The number and type of variants included depend on the laboratory platform. A limited assay cannot exclude rare variants outside the regions tested.

The report must be interpreted using the laboratory's own methodology and clinical comments. Values or metaboliser categories should not be compared directly across laboratories without confirming that the same analytical system and reference criteria were used.

Normal Reporting Time

The report for the TPMT Enzyme Activity (Thiopurine Methyl Transferase) Genotype Study is generally available within 7 to 14 working days. Molecular analysis, specialised enzyme testing, batch processing, technical verification or referral to an external laboratory may affect turnaround time.

Who Should Consider This Test?

• Patients who may begin azathioprine, mercaptopurine or thioguanine treatment.
• People receiving thiopurines for inflammatory bowel disease or autoimmune disorders.
• Patients following oncology or haematology treatment protocols that include thiopurines.
• Individuals who experience unusually severe bone marrow suppression during treatment.
• Patients with a family or personal history suggesting thiopurine intolerance.
• People advised to undergo TPMT or combined TPMT and NUDT15 assessment by a specialist.

Understanding TPMT Results

Normal Activity or Normal Metaboliser: This result suggests that the patient has expected TPMT function based on the method used. It does not guarantee that thiopurine therapy will be effective or free from toxicity. Conventional clinical monitoring is still required.

Intermediate Activity or Intermediate Metaboliser: This finding suggests reduced TPMT function, often associated with one normal-function and one reduced-function allele. The patient may have an increased risk of myelosuppression with conventional dosing. The specialist may use a reduced starting strategy and monitor blood counts closely according to the relevant treatment guideline.

Low or Absent Activity or Poor Metaboliser: This result indicates a high risk of severe toxicity from standard thiopurine doses. Depending on the diagnosis and treatment protocol, the physician may select an alternative treatment or use a substantially modified regimen with intensive monitoring.

High Activity: Some enzyme assays may identify higher-than-expected activity. The clinical meaning depends on the specific assay and treatment context. The result should not be used independently to increase a medicine dose.

Indeterminate or Discordant Result: A result may be inconclusive when genotype and phenotype do not agree or when technical and clinical factors interfere. Repeat analysis, additional variant testing, NUDT15 testing or consultation with the laboratory may be recommended.

Clinical Limitations

TPMT testing does not identify every cause of thiopurine toxicity. Patients with normal TPMT results can still develop severe myelosuppression, liver injury, pancreatitis, infection, gastrointestinal intolerance or other complications. Regular complete blood counts, liver function tests and clinical follow-up remain mandatory.

Enzyme activity may be influenced by recent transfusion, erythrocyte age, blood disorders, medications and assay conditions. Genotyping detects only variants included in the test and may miss rare or novel changes. Genotype cannot measure acquired inhibition of enzyme activity.

TPMT assessment does not replace NUDT15 testing when clinically indicated. It also does not measure the concentrations of active or inactive thiopurine metabolites. Separate thiopurine metabolite testing may be requested during therapy to evaluate adherence, metabolic patterns or treatment optimisation.

The result should not be used by patients to calculate or modify their own dose. Pharmacogenetic recommendations depend on the medicine, diagnosis and clinical protocol. Testing before treatment reduces uncertainty but cannot eliminate all treatment risks.

Important Safety Information

Patients receiving thiopurines should seek prompt medical advice for fever, persistent sore throat, unusual bruising, bleeding, extreme fatigue, mouth ulcers, jaundice, severe abdominal pain or other concerning symptoms. These findings may indicate infection, low blood cell counts, liver injury, pancreatitis or another adverse reaction.

Do not start, stop or change azathioprine, mercaptopurine or thioguanine without instructions from the prescribing specialist. Severe fever, uncontrolled bleeding, breathing difficulty, fainting, confusion or rapidly worsening illness requires urgent medical care. TPMT testing supports treatment planning but never replaces clinical supervision and scheduled laboratory monitoring.